nodes	percent_of_prediction	percent_of_DWPC	metapath
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—FAR2—bile duct cancer	0.00261	0.00261	CbGpPWpGaD
Irbesartan—JUN—Regulation of Telomerase—EGFR—bile duct cancer	0.0026	0.0026	CbGpPWpGaD
Irbesartan—JUN—AP-1 transcription factor network—TGFB1—bile duct cancer	0.00259	0.00259	CbGpPWpGaD
Irbesartan—JUN—DNA Damage Response (only ATM dependent)—ERBB2—bile duct cancer	0.00257	0.00257	CbGpPWpGaD
Irbesartan—JUN—Downstream signaling in naïve CD8+ T cells—KRAS—bile duct cancer	0.00251	0.00251	CbGpPWpGaD
Irbesartan—JUN—ErbB Signaling Pathway—HRAS—bile duct cancer	0.00251	0.00251	CbGpPWpGaD
Irbesartan—JUN—TGF-beta Receptor Signaling—HRAS—bile duct cancer	0.00251	0.00251	CbGpPWpGaD
Irbesartan—JUN—IL2-mediated signaling events—HRAS—bile duct cancer	0.00251	0.00251	CbGpPWpGaD
Irbesartan—JUN—Direct p53 effectors—MMP2—bile duct cancer	0.0024	0.0024	CbGpPWpGaD
Irbesartan—JUN—MAP kinase activation in TLR cascade—IL6—bile duct cancer	0.00233	0.00233	CbGpPWpGaD
Irbesartan—JUN—Fc-epsilon receptor I signaling in mast cells—HRAS—bile duct cancer	0.00228	0.00228	CbGpPWpGaD
Irbesartan—JUN—Focal Adhesion—MET—bile duct cancer	0.00225	0.00225	CbGpPWpGaD
Irbesartan—JUN—TNF alpha Signaling Pathway—NRAS—bile duct cancer	0.00224	0.00224	CbGpPWpGaD
Irbesartan—JUN—ATF-2 transcription factor network—IL6—bile duct cancer	0.00224	0.00224	CbGpPWpGaD
Irbesartan—JUN—Endothelins—HRAS—bile duct cancer	0.00222	0.00222	CbGpPWpGaD
Irbesartan—JUN—LPA receptor mediated events—HRAS—bile duct cancer	0.00219	0.00219	CbGpPWpGaD
Irbesartan—JUN—TSH signaling pathway—HRAS—bile duct cancer	0.00214	0.00214	CbGpPWpGaD
Irbesartan—JUN—Downstream signaling in naïve CD8+ T cells—HRAS—bile duct cancer	0.00214	0.00214	CbGpPWpGaD
Irbesartan—JUN—AP-1 transcription factor network—TP53—bile duct cancer	0.00213	0.00213	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—FAR2—bile duct cancer	0.00213	0.00213	CbGpPWpGaD
Irbesartan—JUN—TCR Signaling Pathway—TGFB1—bile duct cancer	0.00212	0.00212	CbGpPWpGaD
Irbesartan—CYP2C8—Arachidonic acid metabolism—PTGS2—bile duct cancer	0.00211	0.00211	CbGpPWpGaD
Irbesartan—JUN—BCR signaling pathway—HRAS—bile duct cancer	0.00211	0.00211	CbGpPWpGaD
Irbesartan—JUN—Androgen receptor signaling pathway—EGFR—bile duct cancer	0.00209	0.00209	CbGpPWpGaD
Irbesartan—JUN—Circadian rythm related genes—NOS2—bile duct cancer	0.00209	0.00209	CbGpPWpGaD
Irbesartan—PTGS1—Selenium Micronutrient Network—PTGS2—bile duct cancer	0.00208	0.00208	CbGpPWpGaD
Irbesartan—AGTR1—GPCR ligand binding—GNAS—bile duct cancer	0.00205	0.00205	CbGpPWpGaD
Irbesartan—JUN—CDC42 signaling events—HRAS—bile duct cancer	0.00204	0.00204	CbGpPWpGaD
Irbesartan—JUN—ErbB1 downstream signaling—NRAS—bile duct cancer	0.00201	0.00201	CbGpPWpGaD
Irbesartan—JUN—DNA Damage Response (only ATM dependent)—NRAS—bile duct cancer	0.00195	0.00195	CbGpPWpGaD
Irbesartan—JUN—AP-1 transcription factor network—IL6—bile duct cancer	0.00195	0.00195	CbGpPWpGaD
Irbesartan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—bile duct cancer	0.00194	0.00194	CbGpPWpGaD
Irbesartan—JUN—TNF alpha Signaling Pathway—KRAS—bile duct cancer	0.00193	0.00193	CbGpPWpGaD
Irbesartan—JUN—Glucocorticoid receptor regulatory network—TP53—bile duct cancer	0.00188	0.00188	CbGpPWpGaD
Irbesartan—JUN—Senescence and Autophagy in Cancer—TGFB1—bile duct cancer	0.00187	0.00187	CbGpPWpGaD
Irbesartan—JUN—EGF/EGFR Signaling Pathway—ERBB2—bile duct cancer	0.00187	0.00187	CbGpPWpGaD
Irbesartan—JUN—TRAF6 Mediated Induction of proinflammatory cytokines—IL6—bile duct cancer	0.00185	0.00185	CbGpPWpGaD
Irbesartan—JUN—Apoptosis—TP53—bile duct cancer	0.00184	0.00184	CbGpPWpGaD
Irbesartan—JUN—ErbB1 downstream signaling—EGFR—bile duct cancer	0.00184	0.00184	CbGpPWpGaD
Irbesartan—JUN—Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)—HRAS—bile duct cancer	0.00183	0.00183	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—FAR2—bile duct cancer	0.00182	0.00182	CbGpPWpGaD
Irbesartan—JUN—DNA Damage Response (only ATM dependent)—TGFB1—bile duct cancer	0.00182	0.00182	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—FAR2—bile duct cancer	0.0018	0.0018	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—RNF43—bile duct cancer	0.0018	0.0018	CbGpPWpGaD
Irbesartan—UGT1A3—NRF2 pathway—TGFB1—bile duct cancer	0.00178	0.00178	CbGpPWpGaD
Irbesartan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—bile duct cancer	0.00176	0.00176	CbGpPWpGaD
Irbesartan—JUN—PDGFR-beta signaling pathway—NRAS—bile duct cancer	0.00175	0.00175	CbGpPWpGaD
Irbesartan—JUN—Fc epsilon receptor (FCERI) signaling—ERBB2—bile duct cancer	0.00174	0.00174	CbGpPWpGaD
Irbesartan—JUN—ErbB1 downstream signaling—KRAS—bile duct cancer	0.00173	0.00173	CbGpPWpGaD
Irbesartan—JUN—Apoptosis Modulation and Signaling—TP53—bile duct cancer	0.00173	0.00173	CbGpPWpGaD
Irbesartan—CYP2C9—Arachidonic acid metabolism—PTGS2—bile duct cancer	0.00172	0.00172	CbGpPWpGaD
Irbesartan—JUN—Glucocorticoid receptor regulatory network—IL6—bile duct cancer	0.00172	0.00172	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism of lipids and lipoproteins—IDH1—bile duct cancer	0.0017	0.0017	CbGpPWpGaD
Irbesartan—JUN—DNA Damage Response (only ATM dependent)—KRAS—bile duct cancer	0.00168	0.00168	CbGpPWpGaD
Irbesartan—JUN—MyD88 cascade initiated on plasma membrane—IL6—bile duct cancer	0.00167	0.00167	CbGpPWpGaD
Irbesartan—JUN—TCR Signaling Pathway—HRAS—bile duct cancer	0.00167	0.00167	CbGpPWpGaD
Irbesartan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—bile duct cancer	0.00167	0.00167	CbGpPWpGaD
Irbesartan—JUN—TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation—IL6—bile duct cancer	0.00165	0.00165	CbGpPWpGaD
Irbesartan—JUN—Focal Adhesion—ERBB2—bile duct cancer	0.00165	0.00165	CbGpPWpGaD
Irbesartan—JUN—Integrated Pancreatic Cancer Pathway—ERBB2—bile duct cancer	0.00164	0.00164	CbGpPWpGaD
Irbesartan—JUN—TNF alpha Signaling Pathway—HRAS—bile duct cancer	0.00164	0.00164	CbGpPWpGaD
Irbesartan—JUN—MyD88 dependent cascade initiated on endosome—IL6—bile duct cancer	0.00162	0.00162	CbGpPWpGaD
Irbesartan—JUN—Integrated Pancreatic Cancer Pathway—PTGS2—bile duct cancer	0.0016	0.0016	CbGpPWpGaD
Irbesartan—JUN—TCR Signaling Pathway—IL6—bile duct cancer	0.0016	0.0016	CbGpPWpGaD
Irbesartan—JUN—Wnt Signaling Pathway and Pluripotency—TP53—bile duct cancer	0.00158	0.00158	CbGpPWpGaD
Irbesartan—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—bile duct cancer	0.00157	0.00157	CbGpPWpGaD
Irbesartan—JUN—B Cell Receptor Signaling Pathway—HRAS—bile duct cancer	0.00157	0.00157	CbGpPWpGaD
Irbesartan—JUN—TNF alpha Signaling Pathway—IL6—bile duct cancer	0.00157	0.00157	CbGpPWpGaD
Irbesartan—JUN—Toll Like Receptor 9 (TLR9) Cascade—IL6—bile duct cancer	0.00157	0.00157	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—IDH2—bile duct cancer	0.00156	0.00156	CbGpPWpGaD
Irbesartan—JUN—TGF-beta Signaling Pathway—TGFB1—bile duct cancer	0.00156	0.00156	CbGpPWpGaD
Irbesartan—JUN—MyD88:Mal cascade initiated on plasma membrane—IL6—bile duct cancer	0.00154	0.00154	CbGpPWpGaD
Irbesartan—JUN—Senescence and Autophagy in Cancer—TP53—bile duct cancer	0.00154	0.00154	CbGpPWpGaD
Irbesartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—bile duct cancer	0.00152	0.00152	CbGpPWpGaD
Irbesartan—JUN—PDGFR-beta signaling pathway—KRAS—bile duct cancer	0.00151	0.00151	CbGpPWpGaD
Irbesartan—JUN—DNA Damage Response (only ATM dependent)—TP53—bile duct cancer	0.0015	0.0015	CbGpPWpGaD
Irbesartan—JUN—Signaling by NOTCH—TP53—bile duct cancer	0.0015	0.0015	CbGpPWpGaD
Irbesartan—JUN—MyD88-independent cascade—IL6—bile duct cancer	0.00148	0.00148	CbGpPWpGaD
Irbesartan—EDNRA—GPCR downstream signaling—GNAS—bile duct cancer	0.00148	0.00148	CbGpPWpGaD
Irbesartan—JUN—ErbB1 downstream signaling—HRAS—bile duct cancer	0.00147	0.00147	CbGpPWpGaD
Irbesartan—JUN—Senescence and Autophagy in Cancer—HRAS—bile duct cancer	0.00147	0.00147	CbGpPWpGaD
Irbesartan—CYP1A2—Arachidonic acid metabolism—PTGS2—bile duct cancer	0.00147	0.00147	CbGpPWpGaD
Irbesartan—JUN—Direct p53 effectors—EGFR—bile duct cancer	0.00146	0.00146	CbGpPWpGaD
Irbesartan—JUN—Toll-like Receptor Signaling Pathway—IL6—bile duct cancer	0.00144	0.00144	CbGpPWpGaD
Irbesartan—JUN—DNA Damage Response (only ATM dependent)—HRAS—bile duct cancer	0.00143	0.00143	CbGpPWpGaD
Irbesartan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—bile duct cancer	0.00142	0.00142	CbGpPWpGaD
Irbesartan—JUN—Senescence and Autophagy in Cancer—IL6—bile duct cancer	0.00141	0.00141	CbGpPWpGaD
Irbesartan—JUN—Senescence-Associated Secretory Phenotype (SASP)—IL6—bile duct cancer	0.00141	0.00141	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—RNF43—bile duct cancer	0.00141	0.00141	CbGpPWpGaD
Irbesartan—JUN—Oxidative Stress Induced Senescence—TP53—bile duct cancer	0.00139	0.00139	CbGpPWpGaD
Irbesartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—bile duct cancer	0.00138	0.00138	CbGpPWpGaD
Irbesartan—JUN—MAPK Signaling Pathway—NRAS—bile duct cancer	0.00138	0.00138	CbGpPWpGaD
Irbesartan—JUN—Integrated Breast Cancer Pathway—EGFR—bile duct cancer	0.00137	0.00137	CbGpPWpGaD
Irbesartan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—bile duct cancer	0.00136	0.00136	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—IDH1—bile duct cancer	0.00134	0.00134	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—GNAS—bile duct cancer	0.00134	0.00134	CbGpPWpGaD
Irbesartan—JUN—Activated TLR4 signalling—IL6—bile duct cancer	0.00133	0.00133	CbGpPWpGaD
Irbesartan—JUN—Fc epsilon receptor (FCERI) signaling—NRAS—bile duct cancer	0.00133	0.00133	CbGpPWpGaD
Irbesartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—bile duct cancer	0.00131	0.00131	CbGpPWpGaD
Irbesartan—JUN—EGF/EGFR Signaling Pathway—EGFR—bile duct cancer	0.0013	0.0013	CbGpPWpGaD
Irbesartan—JUN—Integrated Breast Cancer Pathway—KRAS—bile duct cancer	0.0013	0.0013	CbGpPWpGaD
Irbesartan—JUN—MAPK Signaling Pathway—TGFB1—bile duct cancer	0.00129	0.00129	CbGpPWpGaD
Irbesartan—JUN—TGF-beta Signaling Pathway—TP53—bile duct cancer	0.00128	0.00128	CbGpPWpGaD
Irbesartan—JUN—PDGFR-beta signaling pathway—HRAS—bile duct cancer	0.00128	0.00128	CbGpPWpGaD
Irbesartan—JUN—MAPK Signaling Pathway—EGFR—bile duct cancer	0.00126	0.00126	CbGpPWpGaD
Irbesartan—JUN—Toll Like Receptor 4 (TLR4) Cascade—IL6—bile duct cancer	0.00125	0.00125	CbGpPWpGaD
Irbesartan—JUN—EGF/EGFR Signaling Pathway—KRAS—bile duct cancer	0.00123	0.00123	CbGpPWpGaD
Irbesartan—JUN—Direct p53 effectors—TP53—bile duct cancer	0.00122	0.00122	CbGpPWpGaD
Irbesartan—CYP1A2—Aryl Hydrocarbon Receptor—NRAS—bile duct cancer	0.00122	0.00122	CbGpPWpGaD
Irbesartan—JUN—Fc epsilon receptor (FCERI) signaling—EGFR—bile duct cancer	0.00121	0.00121	CbGpPWpGaD
Irbesartan—JUN—MAPK Signaling Pathway—KRAS—bile duct cancer	0.00119	0.00119	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—FAR2—bile duct cancer	0.00116	0.00116	CbGpPWpGaD
Irbesartan—JUN—Integrated Pancreatic Cancer Pathway—TGFB1—bile duct cancer	0.00116	0.00116	CbGpPWpGaD
Irbesartan—AGTR1—GPCR downstream signaling—GNAS—bile duct cancer	0.00116	0.00116	CbGpPWpGaD
Irbesartan—JUN—Integrated Breast Cancer Pathway—TP53—bile duct cancer	0.00115	0.00115	CbGpPWpGaD
Irbesartan—JUN—BDNF signaling pathway—HRAS—bile duct cancer	0.00114	0.00114	CbGpPWpGaD
Irbesartan—JUN—Focal Adhesion—EGFR—bile duct cancer	0.00114	0.00114	CbGpPWpGaD
Irbesartan—JUN—Fc epsilon receptor (FCERI) signaling—KRAS—bile duct cancer	0.00114	0.00114	CbGpPWpGaD
Irbesartan—JUN—Integrated Pancreatic Cancer Pathway—EGFR—bile duct cancer	0.00114	0.00114	CbGpPWpGaD
Irbesartan—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TGFB1—bile duct cancer	0.00114	0.00114	CbGpPWpGaD
Irbesartan—PTGS1—Selenium Micronutrient Network—IL6—bile duct cancer	0.00113	0.00113	CbGpPWpGaD
Irbesartan—JUN—Regulation of toll-like receptor signaling pathway—IL6—bile duct cancer	0.00113	0.00113	CbGpPWpGaD
Irbesartan—JUN—Toll-Like Receptors Cascades—IL6—bile duct cancer	0.00111	0.00111	CbGpPWpGaD
Irbesartan—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—bile duct cancer	0.00111	0.00111	CbGpPWpGaD
Irbesartan—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—bile duct cancer	0.00111	0.00111	CbGpPWpGaD
Irbesartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—bile duct cancer	0.00111	0.00111	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—IDH1—bile duct cancer	0.0011	0.0011	CbGpPWpGaD
Irbesartan—JUN—Integrated Pancreatic Cancer Pathway—KRAS—bile duct cancer	0.00107	0.00107	CbGpPWpGaD
Irbesartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—bile duct cancer	0.00106	0.00106	CbGpPWpGaD
Irbesartan—JUN—MAPK Signaling Pathway—TP53—bile duct cancer	0.00106	0.00106	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—RNF43—bile duct cancer	0.00105	0.00105	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—GNAS—bile duct cancer	0.00105	0.00105	CbGpPWpGaD
Irbesartan—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—bile duct cancer	0.00105	0.00105	CbGpPWpGaD
Irbesartan—JUN—Insulin Signaling—HRAS—bile duct cancer	0.00105	0.00105	CbGpPWpGaD
Irbesartan—JUN—EGF/EGFR Signaling Pathway—HRAS—bile duct cancer	0.00104	0.00104	CbGpPWpGaD
Irbesartan—JUN—Myometrial Relaxation and Contraction Pathways—IL6—bile duct cancer	0.00103	0.00103	CbGpPWpGaD
Irbesartan—JUN—SIDS Susceptibility Pathways—IL6—bile duct cancer	0.00103	0.00103	CbGpPWpGaD
Irbesartan—JUN—Cellular Senescence—TP53—bile duct cancer	0.000975	0.000975	CbGpPWpGaD
Irbesartan—JUN—Fc epsilon receptor (FCERI) signaling—HRAS—bile duct cancer	0.00097	0.00097	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—FAR2—bile duct cancer	0.000955	0.000955	CbGpPWpGaD
Irbesartan—JUN—Integrated Pancreatic Cancer Pathway—TP53—bile duct cancer	0.000955	0.000955	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—FAR2—bile duct cancer	0.000947	0.000947	CbGpPWpGaD
Irbesartan—JUN—Fc epsilon receptor (FCERI) signaling—IL6—bile duct cancer	0.000929	0.000929	CbGpPWpGaD
Irbesartan—JUN—Focal Adhesion—HRAS—bile duct cancer	0.000917	0.000917	CbGpPWpGaD
Irbesartan—JUN—Circadian rythm related genes—TP53—bile duct cancer	0.000917	0.000917	CbGpPWpGaD
Irbesartan—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—bile duct cancer	0.000894	0.000894	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—IDH1—bile duct cancer	0.000893	0.000893	CbGpPWpGaD
Irbesartan—JUN—Cellular Senescence—IL6—bile duct cancer	0.000893	0.000893	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—SLC5A5—bile duct cancer	0.000886	0.000886	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—IDH2—bile duct cancer	0.00088	0.00088	CbGpPWpGaD
Irbesartan—JUN—Circadian rythm related genes—IL6—bile duct cancer	0.000839	0.000839	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—TGFBR2—bile duct cancer	0.000821	0.000821	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—FAR2—bile duct cancer	0.000809	0.000809	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—GNAS—bile duct cancer	0.000792	0.000792	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—SMAD4—bile duct cancer	0.000777	0.000777	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—IDH1—bile duct cancer	0.000763	0.000763	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—IDH1—bile duct cancer	0.000756	0.000756	CbGpPWpGaD
Irbesartan—JUN—Cellular responses to stress—TP53—bile duct cancer	0.000737	0.000737	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—GNAS—bile duct cancer	0.000688	0.000688	CbGpPWpGaD
Irbesartan—JUN—Immune System—HGF—bile duct cancer	0.000684	0.000684	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—ERBB2—bile duct cancer	0.000677	0.000677	CbGpPWpGaD
Irbesartan—JUN—Cellular responses to stress—IL6—bile duct cancer	0.000675	0.000675	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—TGFBR2—bile duct cancer	0.000644	0.000644	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—FAR2—bile duct cancer	0.000624	0.000624	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—GNAS—bile duct cancer	0.000622	0.000622	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—SMAD4—bile duct cancer	0.00061	0.00061	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—IDH2—bile duct cancer	0.000568	0.000568	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—NRAS—bile duct cancer	0.00056	0.00056	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—NRAS—bile duct cancer	0.000515	0.000515	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—EGFR—bile duct cancer	0.000511	0.000511	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—SLC5A5—bile duct cancer	0.000499	0.000499	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—IDH1—bile duct cancer	0.000489	0.000489	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—KRAS—bile duct cancer	0.000482	0.000482	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—TGFBR2—bile duct cancer	0.000481	0.000481	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—EGFR—bile duct cancer	0.00047	0.00047	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—bile duct cancer	0.000468	0.000468	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—IDH2—bile duct cancer	0.000466	0.000466	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—GNAS—bile duct cancer	0.000464	0.000464	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—IDH2—bile duct cancer	0.000462	0.000462	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—SMAD4—bile duct cancer	0.000456	0.000456	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—KRAS—bile duct cancer	0.000444	0.000444	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—NRAS—bile duct cancer	0.00044	0.00044	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—ERBB2—bile duct cancer	0.000435	0.000435	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—HRAS—bile duct cancer	0.00041	0.00041	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—IDH1—bile duct cancer	0.000401	0.000401	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—EGFR—bile duct cancer	0.000401	0.000401	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—IDH1—bile duct cancer	0.000398	0.000398	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—IDH2—bile duct cancer	0.000395	0.000395	CbGpPWpGaD
Irbesartan—JUN—Immune System—ERBB2—bile duct cancer	0.000395	0.000395	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—IL6—bile duct cancer	0.000392	0.000392	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—GNAS—bile duct cancer	0.000388	0.000388	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—KRAS—bile duct cancer	0.000378	0.000378	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—HRAS—bile duct cancer	0.000377	0.000377	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—MMP9—bile duct cancer	0.000373	0.000373	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—PTGS2—bile duct cancer	0.00037	0.00037	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—IL6—bile duct cancer	0.000361	0.000361	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—ERBB2—bile duct cancer	0.000341	0.000341	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—IDH1—bile duct cancer	0.00034	0.00034	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—NRAS—bile duct cancer	0.000331	0.000331	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—SLC5A5—bile duct cancer	0.000322	0.000322	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—HRAS—bile duct cancer	0.000322	0.000322	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—IL6—bile duct cancer	0.000308	0.000308	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—TGFB1—bile duct cancer	0.000308	0.000308	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—IDH2—bile duct cancer	0.000305	0.000305	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—bile duct cancer	0.000302	0.000302	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—EGFR—bile duct cancer	0.000302	0.000302	CbGpPWpGaD
Irbesartan—JUN—Immune System—NRAS—bile duct cancer	0.0003	0.0003	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—MMP9—bile duct cancer	0.000293	0.000293	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—KRAS—bile duct cancer	0.000285	0.000285	CbGpPWpGaD
Irbesartan—JUN—Immune System—EGFR—bile duct cancer	0.000273	0.000273	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—SLC5A5—bile duct cancer	0.000265	0.000265	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—SLC5A5—bile duct cancer	0.000262	0.000262	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—IDH1—bile duct cancer	0.000262	0.000262	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—NRAS—bile duct cancer	0.00026	0.00026	CbGpPWpGaD
Irbesartan—JUN—Immune System—KRAS—bile duct cancer	0.000258	0.000258	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—ERBB2—bile duct cancer	0.000255	0.000255	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—TP53—bile duct cancer	0.000253	0.000253	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—GNAS—bile duct cancer	0.00025	0.00025	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—bile duct cancer	0.000246	0.000246	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—HRAS—bile duct cancer	0.000242	0.000242	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—TGFB1—bile duct cancer	0.000241	0.000241	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—EGFR—bile duct cancer	0.000237	0.000237	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—IL6—bile duct cancer	0.000232	0.000232	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—SLC5A5—bile duct cancer	0.000224	0.000224	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—KRAS—bile duct cancer	0.000224	0.000224	CbGpPWpGaD
Irbesartan—JUN—Immune System—HRAS—bile duct cancer	0.00022	0.00022	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—MMP9—bile duct cancer	0.000219	0.000219	CbGpPWpGaD
Irbesartan—JUN—Immune System—IL6—bile duct cancer	0.00021	0.00021	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—bile duct cancer	0.00021	0.00021	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—PTGS2—bile duct cancer	0.000208	0.000208	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—GNAS—bile duct cancer	0.000206	0.000206	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—GNAS—bile duct cancer	0.000204	0.000204	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—TP53—bile duct cancer	0.000199	0.000199	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—NRAS—bile duct cancer	0.000194	0.000194	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—HRAS—bile duct cancer	0.00019	0.00019	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—IL6—bile duct cancer	0.000182	0.000182	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—TGFB1—bile duct cancer	0.00018	0.00018	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—EGFR—bile duct cancer	0.000177	0.000177	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—GNAS—bile duct cancer	0.000174	0.000174	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—SLC5A5—bile duct cancer	0.000173	0.000173	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—KRAS—bile duct cancer	0.000167	0.000167	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—TP53—bile duct cancer	0.000148	0.000148	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—HRAS—bile duct cancer	0.000142	0.000142	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—IL6—bile duct cancer	0.000136	0.000136	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—PTGS2—bile duct cancer	0.000135	0.000135	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—GNAS—bile duct cancer	0.000134	0.000134	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—PTGS2—bile duct cancer	0.00011	0.00011	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—PTGS2—bile duct cancer	0.000109	0.000109	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—PTGS2—bile duct cancer	9.35e-05	9.35e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—PTGS2—bile duct cancer	7.22e-05	7.22e-05	CbGpPWpGaD
